A once-weekly GLP-1 RA

A once-weekly GLP-1 RA

Safety profile established in 8 phase 3a trials, where 4,792 patients were treated with Ozempic® alone or in combination with other glucose-lowering agents1

Rates of hypoglycemia1

Regular self-monitoring of blood glucose to adjust the dose of Ozempic® is not required


When used in combination with a sulfonylurea or basal insulin, there was an increased risk of hypoglycemia with co-administered Ozempic®1


The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogues) or insulin when starting treatment with Ozempic®

Diabetic retinopathy complications1,20

In a 2-year CVOT that investigated 3,297 patients with T2DM, an imbalance in diabetic retinopathy complications was observed in patients with a history of diabetic retinopathy (3% with Ozempic® vs. 1.8% with placebo)


In clinical trials up to 1 year involving 4,807 patients with T2DM, adverse events related to diabetic retinopathy were reported in similar proportions of patients treated with Ozempic® (1.7%) and comparators (2.0%)


Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy


In alignment with Diabetes Canada Guidelines, patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy1,21

CVOT, cardiovascular outcome trial; T2DM, type 2 diabetes mellitus.

Contact Us

Novo Nordisk would like every healthcare practitioner to be able to obtain information as easily and quickly as possible.
If you need information about Ozempic®, please contact:

Novo Nordisk Canada Inc.
101-2476 Argentia Road
Mississauga, Ontario
L5N 6M1

Business hours are:
Monday to Friday from
8:30 a.m. to 5:00 p.m. EST

Main number:
905-629-4222
Toll-free:
1-800-465-4334

Main fax number:
905-629-8662
Toll-free fax number:
1-844-465-2225